Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug resistance in cancer: mechanisms and tackling strategies
Tanweer Haider, Vikas Pandey, Nagma Banjare, et al.
Pharmacological Reports (2020) Vol. 72, Iss. 5, pp. 1125-1151
Closed Access | Times Cited: 220

Showing 1-25 of 220 citing articles:

Emerging role of exosomes in cancer progression and tumor microenvironment remodeling
Mahshid Deldar Abad Paskeh, Maliheh Entezari, Sepideh Mirzaei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 379
Anticancer drug resistance: An update and perspective
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Drug Resistance Updates (2021) Vol. 59, pp. 100796-100796
Open Access | Times Cited: 261
Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance
Shujing Wang, Jingrui Wang, Zhiqiang Chen, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 158
Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges
Chunyan Duan, Mingjia Yu, Jiyuan Xu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114643-114643
Open Access | Times Cited: 139
Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Marta Szumilak, Anna Wiktorowska‐Owczarek, Andrzej Stańczak
Molecules (2021) Vol. 26, Iss. 9, pp. 2601-2601
Open Access | Times Cited: 125
Unveiling the mechanisms and challenges of cancer drug resistance
Sameer Ullah Khan, Kaneez Fatima, Shariqa Aisha, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 107
CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer
Mostafa Vaghari‐Tabari, Parisa Hassanpour, Fatemeh Sadeghsoltani, et al.
Cellular & Molecular Biology Letters (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 74
Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance
Ebrahim H. Maleki, Ahmad Reza Bahrami, Maryam Moghaddam Matin
Genes & Diseases (2023) Vol. 11, Iss. 1, pp. 189-204
Open Access | Times Cited: 65
Nanoparticle-mediated cancer cell therapy: basic science to clinical applications
Jaya Verma, Caaisha Warsame, Rajkumar Kottayasamy Seenivasagam, et al.
Cancer and Metastasis Reviews (2023) Vol. 42, Iss. 3, pp. 601-627
Open Access | Times Cited: 59
Hallmarks of cancer resistance
Muhammad Tufail, Jia-Ju Hu, Jie Liang, et al.
iScience (2024) Vol. 27, Iss. 6, pp. 109979-109979
Open Access | Times Cited: 24
Dietary polyphenols for tumor therapy: bioactivities, nano-therapeutic systems and delivery strategies
Minglu Wang, Ying Wang, Hongyan Zhang
Food & Function (2025)
Closed Access | Times Cited: 2
Etoposide as a Key Therapeutic Agent in Lung Cancer: Mechanisms, Efficacy, and Emerging Strategies
Jung Yoon Jang, Donghwan Kim, Eunok Im, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 796-796
Open Access | Times Cited: 2
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100866-100866
Closed Access | Times Cited: 51
Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials
Syed Nasir Abbas Bukhari
Pharmaceutics (2022) Vol. 14, Iss. 4, pp. 866-866
Open Access | Times Cited: 49
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
Mo Wu, Wei Huang, Nan Yang, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 40
Personalized drug screening in patient-derived organoids of biliary tract cancer and its clinical application
Xiaoxue Ren, Mingle Huang, Weixiang Weng, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101277-101277
Open Access | Times Cited: 27
Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review
Nilesh Kumar Sharma, Anjali Bahot, Gopinath Sekar, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 680-680
Open Access | Times Cited: 17
Phage-based delivery systems: engineering, applications, and challenges in nanomedicines
Hui Wang, Ying Yang, Yan Xu, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 16
Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
Hongquan Wang, Joshua S. Fleishman, Sihang Cheng, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Unlocking the potential of 1,4-naphthoquinones: A comprehensive review of their anticancer properties
Eduardo Angulo-Elizari, Andreina Henriquez-Figuereo, Cristina Morán-Serradilla, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116249-116249
Open Access | Times Cited: 12
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 12
Recent advances of electrospun strategies in topical products encompassing skincare and dermatological treatments
Kaisong Huang, Yifan Si, Chunxia Guo, et al.
Advances in Colloid and Interface Science (2024) Vol. 331, pp. 103236-103236
Closed Access | Times Cited: 11
Advances in the variations and biomedical applications of stimuli-responsive nanodrug delivery systems
Zhongying Gong, Shan Peng, Juanjuan Cao, et al.
Nanotechnology (2024) Vol. 35, Iss. 13, pp. 132001-132001
Closed Access | Times Cited: 10
Long non-coding RNAs in drug resistance across the top five cancers: Update on their roles and mechanisms
Yue Shi, Joseph Adu‐Amankwaah, Qizhong Zhao, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e27207-e27207
Open Access | Times Cited: 9
DDX3X and Stress Granules: Emerging Players in Cancer and Drug Resistance
Han Zhang, Paula M. Mañán-Mejías, Hannah N. Miles, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1131-1131
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top